Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cca.2017.05.017PMID 28514697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification

  2018cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

  2015influential reference
• Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.

  2015cited by this paper
• Lipoprotein-Associated Phospholipase A2 Is Associated with Atherosclerotic Stroke Risk: The Northern Manhattan Study

  2014cited by this paper
• Inflammation, Atherosclerosis and Coronary Artery Disease

  2014cited by this paper
• Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.

  2013cited by this paper
• Lp-PLA2--a novel marker of atherosclerosis: to treat or not to treat?

  2013cited by this paper
• Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study.

  2013cited by this paper
• Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes

  2012cited by this paper
• Phospholipase A 2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes Aggressive

  2012cited by this paper
• Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.

  2012influential reference
• Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

  2011cited by this paper
• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

  2011cited by this paper
• [Lipoprotein associated phospholipase A2].

  2011cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

  2010cited by this paper
• Lipoprotein-Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 Diabetes

  2010influential reference
• Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.

  2008influential reference
• Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.

  2008cited by this paper
• Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.

  2008cited by this paper
• Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

  2008cited by this paper
• Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

  2007cited by this paper
• Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

  2007cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study

  2005cited by this paper
• ATVB in Focus Novel Approaches to the Treatment of Dyslipidemia

  2005influential reference
• Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

  2005cited by this paper
• Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study

  2004cited by this paper
• Consensus Statement

  2004cited by this paper
• CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.

  2004cited by this paper
• Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany

  2004influential reference
• Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Phospholipase A2 enzymes.

  2002influential reference
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• The hazards of scoring the quality of clinical trials for meta-analysis.

  1999influential reference
• Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins.

  1996cited by this paper
• Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

  1995cited by this paper

• Black palladium nanoparticle-based lateral flow immunoassay for cardiovascular disease diagnosis

  2025cites this paper
• Correlation between lipoprotein-associated phospholipase A2 and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: A cross-sectional study.

  2025cites this paper
• The relationships between biological novel biomarkers Lp‐PLA2 and CTRP‐3 and CVD in patients with type 2 diabetes mellitus

  2024cites this paper
• Correlation of LP-PLA2 and MMP-9 with the occurrence of early neurological deterioration in patients with acute ischemic stroke

  2024cites this paper
• Novel Electrochemiluminescent Immunosensor Using Dual Amplified Signals from a CoFe Prussian Blue Analogue and Au Nanoparticle for the Detection of Lp-PLA2.

  2023cites this paper
• Risk factors for acute ischemic stroke in patients with type 2 diabetes mellitus

  2023influential citation
• Significance of determination of lipoprotein-associated Phospholipase A2 in patients with antiphospholipid syndrome

  2023cites this paper
• Biomarkers in aneurysmal subarachnoid hemorrhage: A short review

  2023cites this paper
• Compliance, Adherence and Concordance Differently Predict the Improvement of Uremic and Microbial Toxins in Chronic Kidney Disease on Low Protein Diet

  2022cites this paper
• Does Mediterranean Adequacy Index Correlate with Cardiovascular Events in Patients with Advanced Chronic Kidney Disease? An Exploratory Study

  2022cites this paper
• A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke

  2022cites this paper
• Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial

  2022cites this paper
• Phospholipase A2 and Ischemic Stroke Etiology

  2021cites this paper
• The relationship between the carotid atherosclerosis ultrasound parameters and the cardiac and endothelial functions of coronary heart disease patients.

  2021cites this paper
• Hypothesis of “stroke-stop” formula: a tool for risk index determination in development of acute cerebrovascular disease in asymptomatic individuals with carotid stenosis

  2021cites this paper
• Lp‐PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke‐risk populations

  2021cites this paper
• Inflammatory markers in cardiovascular disease; lessons learned and future perspectives.

  2020cites this paper
• Cardiovascular Disease Risk Tests (for Nebraska Only)-Community Plan Medical Policy

  2020cites this paper
• Cardiovascular Disease Risk Tests – Community Plan Medical Policy

  2020cites this paper
• Cardiovascular Disease Risk Tests (for Tennessee Only)-Community Plan Medical Policy

  2020cites this paper
• Cardiovascular Disease Risk Tests (for Louisiana Only)-Community Plan Medical Policy

  2020cites this paper
• Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?

  2020cites this paper
• Cardiovascular Disease Risk Tests – Oxford Clinical Policy

  2020cites this paper
• Andrographolide protects against endothelial dysfunction and inflammatory response in rats with coronary heart disease by regulating PPAR and NF-κB signaling pathways.

  2020cites this paper
• 10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020

  2020cites this paper
• Au-coated Fe3O4 core-shell nanohybrids with photothermal activity for point-of-care immunoassay for lipoprotein-associated phospholipase A2 on a digital near-infrared thermometer

  2020cites this paper
• Probiotics-addicted low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): A protocol of placebo-controlled randomized trial

  2020cites this paper
• Risk Factor Differences in Calcified and Non-Calcified Cervical Carotid Plaque

  2020cites this paper
• The role of lipoprotein-associated phospholipase A2 in acute kidney injury of septic mice

  2020cites this paper
• “Stroke-Stop” Formula: A Tool for Risk Index Determination in Development of Acute Cerebrovascular Disease in Patients with Asymptomatic Internal Carotid Artery Stenosis

  2020cites this paper
• Cardiovascular Disease Risk Tests – Commercial Medical Policy

  2020cites this paper
• Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression.

  2019cites this paper
• Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.

  2019cites this paper
• An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

  2019cites this paper
• Resveratrol protects myocardial apoptosis induced by ischemia-reperfusion in rats with acute myocardial infarction via blocking P13K/Akt/e-NOS pathway.

  2019cites this paper
• Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study

  2019cites this paper
• Sensitive and portable electrochemical immunoassay for lipoprotein-associated phospholipase A2 using BSA-doped CaCO3 nanospheres to regulate pH readout

  2019cites this paper
• Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.

  2019cites this paper
• Comparison of serum Lp‐PLA2 levels in ischemic stroke patients with H‐type hypertension or non‐H‐type hypertension

  2019cites this paper
• Letter by Li et al Regarding Article, "NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke".

  2019cites this paper
• Lipoprotein‐associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects

  2019cites this paper
• Cardiovascular Disease Risk Tests

  2019cites this paper
• Cardiovascular Disease Risk Tests

  2018cites this paper
• Cardiovascular Disease Risk Tests

  2018cites this paper
• Cardiovascular Disease Risk Tests

  2018cites this paper
• Cardiovascular Disease Risk Tests

  2018cites this paper
• Change of Inflammatory Factors in Patients with Acute Coronary Syndrome

  2018cites this paper
• Metabolomics and Lipidomics of Ischemic Stroke.

  2018cites this paper
• Endothelial stem cells attenuate cardiac apoptosis via downregulating cardiac microRNA-146a in a rat model of coronary heart disease.

  2018cites this paper
• Measuring lipoprotein‐associated phospholipase A2 activity in China: Protocol comparison and recalibration

  2018cites this paper
• Lipoprotein-Associated Phospholipase A2: A Risk Factor for Ischemic Stroke?

  2018cites this paper
• Cardiovascular Disease Risk Tests

  2018cites this paper
• Cardiovascular Disease Risk Tests

  2017cites this paper
• Cardiovascular Disease Risk Tests

  year unknowncites this paper
• Cardiovascular Disease Risk Tests

  year unknowncites this paper
• Cardiovascular Disease Risk Tests

  year unknowncites this paper
• Cardiovascular Disease Risk Tests

  year unknowninfluential citation
• Cardiovascular Disease Risk Tests (for New Mexico Only)

  year unknowncites this paper
• Cardiovascular Disease Risk Tests (for Ohio Only)

  year unknowncites this paper
• Cardiovascular Disease Risk Tests (for Louisiana Only)

  year unknowncites this paper
• Cardiovascular Disease Risk Tests (for North Carolina Only)

  year unknowncites this paper
• Cardiovascular Disease Risk Tests

  year unknowncites this paper
• Cardiovascular Disease Risk Tests

  year unknowncites this paper